News

Shares of Earth-imaging satellites company BlackSky Technology (NYSE: BKSY) soared 13.5% through 3 p.m. ET Thursday -- probably because of a couple of tweets posted on X announcing BlackSky's plans

A rocky road for Summit Therapeutics got a lot rougher over the weekend. The company presented somewhat disappointing data for the experimental cancer drug it's developing.

When the market opened on

Shares of EchoStar (NASDAQ: SATS) jumped on Wednesday, closing the day up 15.5%. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) and the Nasdaq Composite (NASDAQINDEX: ^IXIC) both ticked up

Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of

U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%

We're well into the home stretch of 2025. August is more than halfway over. But there's still plenty of time remaining in the year -- and in this month -- to invest in stocks that hold the potential

SurgePays (NASDAQ:SURG) reported its fiscal Q2 2025 earnings on August 5, 2025 (for the quarter ended June 30, 2025), with revenue rose 8.9% quarter over quarter to $11.5 million and issued revenue

Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a biotechnology company specializing in engineered T-cell therapies for cancer, released its second-quarter earnings on August 13, 2025, covering results

AstraZeneca (NASDAQ: AZN) reported an estimates-busting quarter Tuesday morning, and a satisfied market rewarded the company for it. At market close the sturdy pharmaceutical stock had risen by

Investors looking to grow their passive income stream with dividend stocks have two basic options. Dividend payers that raise their payouts rapidly tend to offer low yields up front, while

AT&T (NYSE: T) has quietly been a great-performing stock over the past couple of years, but it has pulled back after the company failed to raise its guidance when it reported its second quarter

On July 10, 2025, Stewart Murray Lee (Head of People & Strategy) executed an open market sale of 50,000 shares of New Horizon Aircraft Ltd.(NASDAQ:HOVR), with the transaction disclosed in a Form 4

AT&T (NYSE: T) released its latest set of quarterly results Wednesday morning. While these weren't strong enough to bring the bulls charging into the stock, they were nevertheless pleasing for

AT&T (NYSE:T), a U.S. telecommunications and connectivity provider, released its Q2 2025 earnings on July 23, 2025. The company posted adjusted earnings per share of $0.54, just above the average

First Horizon (NYSE:FHN), a regional banking group focused on retail and commercial lending in the Southeast, released its second quarter 2025 earnings on July 16, 2025. The most important news was

AT&T (NYSE:T), a major U.S. telecommunications company known for wireless and fiber broadband services, released its second-quarter 2025 results on July 23, 2025. The company reported revenue of

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially

AT&T (NYSE: T) stock moved higher in Monday's trading. The telecommunications company's share price gained 1.6% in the daily session amid a 0.1% gain for the S&P 500 index and a 0.3% gain for the

Three years ago, Summit Therapeutics (NASDAQ: SMMT) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time

Is it worth it to buy a stock after it experiences significant market gains? The answer is, it depends. Some companies don't have much growth fuel left in the tank after a nice run, while others

Regardless of the number of tools and resources available to Wall Street or the average investor, there's no way to predict how a stock's price will move with 100% certainty.

However, one thing that

AstraZeneca (NASDAQ: AZN) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that

One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (NASDAQ: SMMT) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped

Trading in AstraZeneca's (NASDAQ: AZN) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly

What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender. The reality is that it doesn't take much up-front cash.

Three